Tafluprost, a new potent prostanoid receptor agonist: A dose-response study on pharmacodynamics and tolerability in healthy volunteers

Sutton A., Gouws P., Ropo A.

2008
International Journal of Clinical Pharmacology and Therapeutics

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Guildford Clinical Pharmacology Ltd., Technology Center, Guildford, Surrey, United Kingdom; Conquest Hospital, Ridge, St. Leonards-on-Sea, East Sussex, United Kingdom; Santen Oy Clinical Research, Tampere, Finland; Cedars Vanzell Road, Midhurst, West Sussex GU29 9BA, United Kingdom

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.

Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

View all Glaucoma publications